{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:35:37Z","timestamp":1763116537897,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10147-017-1141-y","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T03:17:39Z","timestamp":1495768659000},"page":"972-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-4971","authenticated-orcid":false,"given":"Masayuki","family":"Shiseki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Kouzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"1141_CR2","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758\u20133765","journal-title":"Blood"},{"key":"1141_CR3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851","journal-title":"Lancet Oncol"},{"key":"1141_CR4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123\u20131129","journal-title":"Blood"},{"key":"1141_CR5","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC et al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175","journal-title":"Leukemia"},{"key":"1141_CR6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"1141_CR7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"1141_CR8","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"1141_CR9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398\u20131405","journal-title":"Leukemia"},{"key":"1141_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H et al (2009) Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135\u2013139","journal-title":"Haematologica"},{"key":"1141_CR11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S et al (2010) Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 91:799\u2013807","journal-title":"Int J Hematol"},{"key":"1141_CR12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772\u2013782","journal-title":"Blood"},{"key":"1141_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.leukres.2014.04.004","volume":"38","author":"AE Eskazan","year":"2014","unstructured":"Eskazan AE, Eyice D, Kurt EA et al (2014) Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res 38:781\u2013787","journal-title":"Leuk Res"},{"key":"1141_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","volume":"99","author":"T Kumagai","year":"2014","unstructured":"Kumagai T, Matsuki E, Inokuchi K et al (2014) Relative increase in lymphocytes from as early as 1\u00a0month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 99:41\u201352","journal-title":"Int J Hematol"},{"key":"1141_CR15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C et al (2015) Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol 90:819\u2013824","journal-title":"Am J Hematol"},{"key":"1141_CR16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K et al (2012) Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17:584\u2013589","journal-title":"Int J Clin Oncol"},{"key":"1141_CR17","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1\u00a0year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528\u2013e535","journal-title":"Lancet Haematol"},{"key":"1141_CR18","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"1141_CR19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.leukres.2010.12.006","volume":"35","author":"T Ono","year":"2011","unstructured":"Ono T, Miyawaki S, Kimura F et al (2011) BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res 35:598\u2013603","journal-title":"Leuk Res"},{"key":"1141_CR20","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303\u20132309","journal-title":"Blood"},{"key":"1141_CR21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N et al (2014) Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124:729\u2013736","journal-title":"Blood"},{"key":"1141_CR22","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"},{"key":"1141_CR23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA et al (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765\u2013770","journal-title":"Leukemia"},{"key":"1141_CR24","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","volume":"112","author":"A Giannoudis","year":"2008","unstructured":"Giannoudis A, Davies A, Lucas CM et al (2008) Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112:3348\u20133354","journal-title":"Blood"},{"key":"1141_CR25","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D et al (2005) Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 19:1774\u20131782","journal-title":"Leukemia"},{"key":"1141_CR26","doi-asserted-by":"crossref","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","volume":"285","author":"T Pene-Dumitrescu","year":"2010","unstructured":"Pene-Dumitrescu T, Smithgall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285:21446\u201321457","journal-title":"J Biol Chem"},{"key":"1141_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Br\u00fcmmendorf TH (2014) Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol 11:89\u201399","journal-title":"Drug Discov Today Technol"},{"key":"1141_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","volume":"184","author":"A Gontarewicz","year":"2010","unstructured":"Gontarewicz A, Br\u00fcmmendorf TH (2010) Danusertib (formerly PHA-739358)\u2014a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 184:199\u2013214","journal-title":"Recent Results Cancer Res"},{"key":"1141_CR29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 85:387\u2013398","journal-title":"Eur J Haematol"},{"key":"1141_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","volume":"94","author":"H Hjorth-Hansen","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, S\u00f6derlund S et al (2015) Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 94:243\u2013250","journal-title":"Eur J Haematol"},{"key":"1141_CR31","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"1141_CR32","first-page":"355","volume":"57","author":"H Klamova","year":"2010","unstructured":"Klamova H, Faber E, Zackova D et al (2010) Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma 57:355\u2013359","journal-title":"Neoplasma"},{"key":"1141_CR33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"1141_CR34","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","volume":"12","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Radich JP, Abboud CN et al (2014) Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 12:1590\u20131610","journal-title":"J Natl Compr Canc Netw"},{"key":"1141_CR35","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024\u20131029","journal-title":"Am J Hematol"},{"key":"1141_CR36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G, Dulucq S, Nicolini FE et al (2014) Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 99:458\u2013464","journal-title":"Haematologica"},{"key":"1141_CR37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423","journal-title":"J Clin Oncol"},{"key":"1141_CR38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB et al (2016) Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk 16:286\u2013296","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1141_CR39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahl\u00e9n","year":"2016","unstructured":"Dahl\u00e9n T, Edgren G, Lambe M et al (2016) Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med 165:161\u2013166","journal-title":"Ann Intern Med"},{"key":"1141_CR40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"1141_CR41","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719\u20131724","journal-title":"Leukemia"},{"key":"1141_CR42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y et al (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903\u2013906","journal-title":"Haematologica"},{"key":"1141_CR43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"1141_CR44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","volume":"88","author":"SE Lee","year":"2013","unstructured":"Lee SE, Choi SY, Bang JH et al (2013) Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol 88:449\u2013454","journal-title":"Am J Hematol"},{"key":"1141_CR45","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90:910\u2013914","journal-title":"Am J Hematol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1141-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T13:31:21Z","timestamp":1506000681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1141-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2017,5,26]]}}}